Home / Stocks / Dr. Reddy S Laboratories
DRREDDY

Dr. Reddy S Laboratories Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,400.9

Change

+2.7 (0.19%)

Open

₹1,398.0

Prev. Close

₹1,398.2

Day High

₹1,402.7

Day Low

₹1,379.1

Volume Analysis

Traded

1,451,283

Delivered

824,984

Delivery %

56.85%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Trading within 3% of its 52-week high (₹1415.0)

Weaknesses (0)

No signal for this stock

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,432.96 ₹1,417.83 ₹1,409.36 ₹1,394.23 ₹1,385.76 ₹1,370.63 ₹1,362.16
Fibonacci ₹1,417.83 ₹1,408.81 ₹1,403.25 ₹1,394.23 ₹1,385.21 ₹1,379.65 ₹1,370.63
Camarilla ₹1,407.39 ₹1,405.23 ₹1,403.06 ₹1,394.23 ₹1,398.74 ₹1,396.57 ₹1,394.41

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+11.77%

1 Week

+1.03%

1 Month

+12.57%

3 Months

+19.26%

6 Months

+7.17%

1 Year

+12.2%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹725.22

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

7.21%

Net margin 8.34% × asset turnover 0.58x × equity multiplier 1.49x

Company Overview

Sector

Healthcare

Market Cap

₹115,092 Cr

P/E (TTM)

41.1

ROE

11.2%

Book Value

₹465.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Dr. Reddy S Laboratories holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Valuation (32/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹1415.0). FII holding has been falling.

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

49

Valuation

32

Cash Flow

59

Corporate Governance

61

Momentum

89

Institutional Ownership

69

Business Quality

59

Risk & Volatility

76

Liquidity

75

From Screener.in

  • +Company's working capital requirements have reduced from 85.1 days to 67.8 days
  • −Dividend payout has been low at 13.2% of profits over last 3 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 6,903 7,237 7,114 7,696 8,038 8,381 8,528 8,572 8,828 8,753 7,546 8,100 8,698
Expenses + 4,894 5,214 5,283 5,566 5,962 6,108 6,530 6,398 6,818 6,866 7,164 7,240 6,975
Operating Profit 2,008 2,023 1,831 2,130 2,076 2,273 1,998 2,174 2,010 1,888 382 860 1,723
OPM % 29.0% 28.0% 26.0% 28.0% 26.0% 27.0% 23.0% 25.0% 23.0% 22.0% 5.0% 11.0% 20.0%
Other Income + 319 219 201 193 314 154 528 290 330 271 480 356 156
Interest 35 39 59 60 76 82 66 83 91 94 106 126 125
Depreciation 376 374 368 381 397 471 455 476 505 521 557 537 527
Profit before tax 1,917 1,829 1,605 1,883 1,917 1,874 2,005 1,905 1,745 1,543 200 553 1,228
Tax % 23.0% 24.0% 18.0% 26.0% 30.0% 25.0% 21.0% 26.0% 23.0% 23.0% -11.0% 21.0% 26.0%
Net Profit + 1,482 1,381 1,310 1,392 1,342 1,404 1,587 1,410 1,337 1,190 221 436 913
EPS in Rs 18 17 16 17 15 17 19 17 16 15 3 5 11
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 9 7 13 14 16 16 20 11 10 4 -12 -6 -1

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 15,023 15,568 14,196 14,281 15,448 17,517 19,048 21,545 24,670 28,011 32,644 33,700 33,097
Expenses + 11,515 11,983 11,724 11,930 12,270 15,040 15,173 17,778 18,200 20,078 24,097 27,247 28,245
Operating Profit 3,508 3,585 2,472 2,351 3,178 2,477 3,874 3,768 6,470 7,933 8,547 6,454 4,853
OPM % 23.0% 23.0% 17.0% 16.0% 21.0% 14.0% 20.0% 17.0% 26.0% 28.0% 26.0% 19.0% 15.0%
Other Income + 260 295 172 155 381 670 335 555 971 909 1,119 1,372 1,263
Interest 108 83 63 79 89 98 97 96 143 171 283 374 450
Depreciation 760 939 1,027 1,077 1,135 1,163 1,229 1,165 1,250 1,470 1,704 2,059 2,141
Profit before tax 2,900 2,859 1,554 1,350 2,336 1,886 2,884 3,061 6,048 7,201 7,680 5,393 3,524
Tax % 19.0% 26.0% 19.0% 32.0% 17.0% -7.0% 32.0% 29.0% 25.0% 23.0% 25.0% 23.0% —
Net Profit + 2,336 2,131 1,292 947 1,950 2,026 1,952 2,182 4,507 5,578 5,725 4,158 2,760
EPS in Rs 27 25 16 11 23 24 23 26 54 67 68 50 34
Dividend Payout % 15.0% 16.0% 26.0% 35.0% 17.0% 21.0% 21.0% 23.0% 15.0% 12.0% 12.0% 16.0% —
Sales growth 12 4 -9 1 8 13 9 13 14 14 17 3 -4

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 9,768 12,484 12,179 12,489 13,941 15,516 17,558 19,129 23,203 28,171 33,466 37,808 38,724
Borrowings + 4,314 3,352 4,918 5,071 3,838 2,210 3,031 3,384 1,347 2,002 4,677 7,734 7,229
Other Liabilities + 4,290 4,408 4,474 4,706 4,557 5,414 5,915 7,149 7,576 8,523 9,797 10,951 11,596
Total Liabilities 18,457 20,330 21,654 22,349 22,418 23,223 26,588 29,746 32,209 38,780 48,023 56,577 57,631
Fixed Assets + 5,377 6,563 6,931 6,968 7,191 6,850 8,206 8,122 9,219 10,426 18,226 22,063 22,173
CWIP 529 772 3,324 3,470 2,934 1,535 1,565 1,293 1,030 1,419 2,466 1,460 1,207
Investments 2,248 3,833 2,110 2,298 2,587 2,678 2,212 2,616 4,986 4,930 4,051 5,285 4,502
Other Assets + 10,303 9,162 9,290 9,612 9,707 12,160 14,605 17,715 16,974 22,004 23,280 27,768 29,749
Total Assets 18,457 20,330 21,654 22,349 22,418 23,223 26,588 29,746 32,209 38,780 48,023 56,577 57,631
Equity Capital 85 85 83 83 83 83 83 83 83 83 83 84 84

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 2,524 3,263 2,144 1,803 2,870 2,984 3,570 2,811 5,888 4,543 4,643 5,674
Cash from Investing Activity + -2,370 -1,610 -1,890 -1,483 -769 -495 -2,255 -2,565 -4,109 -4,034 -5,785 -6,425
Cash from Financing Activity + -433 -1,700 -369 -444 -2,133 -2,516 -30 -242 -2,686 -376 1,891 829
Net Cash Flow -280 -47 -114 -124 -31 -27 1,286 3 -907 133 749 78
Free Cash Flow 1,009 2,065 926 713 2,248 2,412 2,323 1,238 4,009 1,908 1,327 2,004
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 88 111 110 88 106 149 107 94 108 83 78 109

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 26.65% → 26.63%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Others 0.18% 0.17% 0.17% 0.16% 0.16% 0.29% 0.26% 0.25% 0.25% 0.24% 0.2% 0.19%
Public 25.89% 25.73% 24.78% 24.2% 23.46% 21.69% 21.04% 20.45% 20.33% 21.27% 20.76% 20.99%
Promoters 26.65% 26.65% 26.65% 26.64% 26.64% 26.64% 26.64% 26.64% 26.64% 26.63% 26.63% 26.63%
FII 28.62% 29.13% 27.68% 27.53% 26.85% 25.75% 25.33% 24.69% 22.34% 21.14% 20.67% 20.3%
DII 18.65% 18.31% 20.72% 21.48% 22.89% 25.63% 26.73% 27.99% 30.44% 30.72% 31.75% 31.87%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Dr. Reddy S Laboratories (this stock) 115,092 41.1 2.96 11.2%
Cipla Ltd 112,563 36.2 3.18 11.6%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%
Mankind Pharma Limited 108,424 46.5 6.16 13.1%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Aurobindo Pharma Ltd 104,215 25.7 2.64 10.1%

Which Mutual Funds Hold Dr. Reddy S Laboratories?

Frequently Asked Questions about Dr. Reddy S Laboratories

Community Sentiment

What are other investors saying about Dr. Reddy S Laboratories?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.